
US Expat. Senior Machine Learning Scientist @Inflammatix_Inc. All views are my own and subject to update with more evidence.
Burlingame, CA / Cambridge, UK
Joined July 2016
- Tweets1.4K
- Following337
- Followers190
- Likes1.6K
Michael Mayhew retweeted
Towards Equitable Patient Subgroup Performance by Gene-Expression-Based Diagnostic Classifiers of Acute Infection medrxiv.org/cgi/content/shor… #medRxiv
Michael Mayhew retweeted
Tomorrow: Join Inflammatix at #SAEM21 where we will present, “When Assessing Infection and Sepsis in the ED, Think Patient, Not Pathogen: Use Immune Response for Diagnosis & COVID-19 Severity Risk Prediction” on 5/12 at 12 CST
Register here: saem.org/meetings-and-events…
@LSMayMD
#SAEM21 will be everything you love about our in-person meeting, reimagined & repackaged in a top-notch digital format. Watch live content, participate in interactive Q&A, engage with speakers, & connect with your peers. Register today! ow.ly/FzdL50EfwPM
Michael Mayhew retweeted
If you would like to work on state-of-of-the-art algorithms and software for helping patients with infections and other immune-system-related diseases, consider joining the @Inflammatix_Inc Machine Learning team:
linkedin.com/jobs/view/25041…
linkedin.com/jobs/view/24837…
Michael Mayhew retweeted
We are thrilled to announce the appointment of med device executive Amy Boyle as COO. Ms. Boyle brings 30 yrs of commercial med device experience, with expertise in strategy, market development, sales & marketing, commercial operations, and manufacturing. businesswire.com/news/home/2…
Michael Mayhew retweeted
“By quickly providing actionable information about disease, Inflammatix expects to equip physicians to make better clinical decisions that benefit both patients and healthcare systems,” said CEO @TimSweeney83. fiercebiotech.com/medtech/in… @FierceBiotech bit.ly/3tfeBu5
Michael Mayhew retweeted
Moving beyond "algorithmic bias is a data problem"
An extended perspective piece in @Patterns_CP
How do our model design choices contribute to algorithmic bias?
bit.ly/3wLJtnY
Michael Mayhew retweeted
Our InSep acute infection and sepsis test in development will help physicians determine whether a patient has a #bacterial or #viral infection anywhere in the body, and how #severe it may become. Learn more: inflammatix.com
Michael Mayhew retweeted
We are also starting to engage and initiate programs that will support development of effective #data policies in Africa. We call upon you to be apart of the effort aimed at building a database of data driven #COVID19 response solutions in Africa 👉 cutt.ly/wx0QITc
Michael Mayhew retweeted
DSA is excited to announce a visiting fellowship program for members of our community to further their professional and personal development through academic and professional research visits. Learn more 👉 datascienceafrica.org/dsa-vi…
Michael Mayhew retweeted
Congratulations to @red_abebe , @wsisaac , @shakir_za and @png_marie for contributing to this new book exploring work, democracy & justice in the context of Artificial Intelligence Development!
We are thrilled to announce our new book: REDESIGNING AI — coming later this spring!
Exploring work, democracy, & justice in the age of automation, it features @DrDaronAcemoglu, @erikbryn, @math_rachel, @katecrawford, @shakir_za (+ more 🧵)
Preorder now: store.bostonreview.net/backi…
Michael Mayhew retweeted
Thrilled to announce our $102M Series D as we make major strides towards clinical deployment of rapid host-response #diagnostics for acute infections and #sepsis! Welcome D1 Capital! And huge thanks to the @Inflammatix_Inc team- I am so grateful to work with you every day!
We are delighted to announce the closing of a $102 million Series D round of financing to support development and commercialization of our novel immune response diagnostics portfolio. Read press release: businesswire.com/news/home/2…
Michael Mayhew retweeted
We are delighted to announce the closing of a $102 million Series D round of financing to support development and commercialization of our novel immune response diagnostics portfolio. Read press release: businesswire.com/news/home/2…
Michael Mayhew retweeted
New review article aids in the understanding and interpretation of sepsis subtypes, provides a mechanism for explaining subtypes generated by different methodologic approaches, and guides clinicians in how to consider subtypes in bedside care: journals.lww.com/ccmjournal/…
Michael Mayhew retweeted
We are excited to announce that @DeepMind has partnered with @MakerereU to establish fully paid scholarships to study #AI and Machine Learning at @MakCoCIS
#DataScience
#MachineLearning
news.mak.ac.ug/2021/02/deepm…
Michael Mayhew retweeted
.@DeepMind set to fund four scholarships in the field of Machine Learning beginning in the academic year 2021/2022. The scholarships will support students to study MSc. Computer Science programme (Track: AI and Data Science) at Makerere University. news.mak.ac.ug/2021/02/deepm…
Michael Mayhew retweeted
ED providers & researchers face the ongoing challenge to develop, evaluate and implement tools that will permit earlier, faster & more reliable detection of patients w/ suspected #infections. Learn more on our innovative host response tests in development: inflammatix.com/presents/
Michael Mayhew retweeted
Signatures under development @Inflammatix_Inc can detect presymptomatic AND asymptomatic COVID, as measured by a fully independent group! 👀👀
A rapid blood test that can detect infections prior to PCR positivity could be a major aid to screening efforts!
Congratulation @mnoursad and @Rishi_K_Gupta on this much needed analysis (and thank you for including 3 signatures from our lab). Some thoughts below 1/n
Michael Mayhew retweeted
The #Inflammatix diagnostic tests in development will read the body's innate immune system. This is the body’s 1st line of defense in the presence of #infection. It kicks in immediately, has abundant identifiable biomarkers throughout the body and can be measured in minutes.
Michael Mayhew retweeted
“When translated into a rapid, point-of-care test, InSep could provide ED physicians with actionable results supporting early informed treatment decisions to improve patient outcomes while upholding antimicrobial stewardship.” Read article: medrxiv.org/content/10.1101/…
Michael Mayhew retweeted
A #Multi-mRNA Host-Response Molecular Blood Test for the Diagnosis and Prognosis of Acute Infections and #Sepsis by Dr. James Ducharme etc. @McMasterU mdpi.com/916404 via @MDPIOpenAccess























